Hims & Hers Health: Analysts remain bearish

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/29/2026

1. NOW
2. MSFT
3. GOOGL
4. FTNT
5. TENB
6. EBAY
7. CMG
8. KLAC
9. GOOG
10. BIIB

Go back to Hims & Hers Health: Analysts remain bearish

Citi Drops Third Note on Hims and Hers (HIMS) Inside 20 Hours: 'HIMS is now offering discounts on its bundles, effectively passing through the price discount'

May 22, 2025 2:50 PM EDT

(Updated - May 22, 2025 2:52 PM EDT)

Citi analyst Daniel Grosslight reiterated a Sell rating and $30.00 price target on Hims and Hers (NYSE: HIMS)

The analyst comments "In response to Novo lowering the cash pay price of Wegovy to $199 for the first month... More

Citi Reiterates Sell Rating on Hims and Hers (HIMS), Comments on Novo's Wegovy Price Promo: 'We see this as another potential headwind for HIMS

May 22, 2025 11:34 AM EDT

Citi analyst Daniel Grosslight reiterated a Sell rating and $30.00 price target on Hims and Hers (NYSE: HIMS)

The analyst comments "With the end of 503B bulk compounding of commercially available semaglutide today, NovoCare announced a promotion offering cash pay access to Wegovy for $199... More